SYNTHESIS & CHARACTERIZATION OF NEW MACROMOLECULAR CONTRAST AGENTS

合成

• 批准号: 7724164
• 负责人: Robert Charles Brasch
• 金额: $ 0.31万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2009-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7724164
• 关键词: Blood; Categories; Characteristics; Chemicals; Class; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Data; Diagnostic; Effectiveness; Electrons; Funding; Grant; Image; Institution; MALDI-TOF Mass Spectrometry; Mass Spectrum Analysis; Measurement; Medical Imaging; Microvascular Permeability; Molecular; Molecular Weight; Organ; Pharmacologic Substance; Pliability; Property; Research; Research Personnel; Resources; Role; Source; Structure; Tissues; United States National Institutes of Health; cancer imaging; ionization; size; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Imaging contrast agents (or contrast media) are a category of diagnostic pharmaceuticals for enhancing the image contrast of organs/tissues and for displaying the organ function in medical imaging. Macromolecular contrast agents have found their important role in the characterization of microvascular permeability/leakiness of tumor vessels, due to their blood-pool characteristics. New polyethyleneglycol (PEG)-core dendrimeric contrast agents with well-defined structure, high degree of size homogeneity, synthetic flexibility, and high effectiveness in imaging, have been synthesized. Their average molecular weights (MW) and MW distribution will be obtained from mass spectrometry, which info will be highly valuable for the study of their structure-property relationship and for the guidance of our synthetic optimization. In addition, those new small molecular intermediates, which are attributed to the image contrast, need the structure characterization by mass spectrometry. For different macromolecular derivatives (MW 3,000 - 90,000), matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry is used for the measurements of their MW and MW distributions. For small molecular compounds (MW 100 - 2000), electron spray ionization (ESI) mass spectrometry is applicable. Mass spectra data will be correlated with the data from physical and imaging measurements, the relationship among chemical, physical and imaging properties will be sought for this new class of dendrimeric contrast agents. The mass spectra data are highly important and valuable in the synthesis of our new PEG-core dendrimeric contrast agents for cancer imaging.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 成像造影剂（或造影剂）是一类诊断药物，用于增强器官/组织的图像对比度，并用于在医学成像中显示器官功能。大分子造影剂由于其血池特性，在肿瘤血管的微血管渗透性/渗漏的表征中具有重要作用。已经合成了新型聚乙二醇（PEG）核树枝状聚合造影剂，具有结构明确、尺寸均匀性高、合成灵活性和成像高效性。通过质谱分析得到了它们的平均分子量和分子量分布，这些信息对研究它们的结构与性能的关系以及指导合成优化具有重要的参考价值。另外，由于图像反差的原因，一些新的小分子中间体需要质谱进行结构表征。对于不同的大分子衍生物（MW 3，000 - 90，000），基质辅助激光解吸电离飞行时间（MALDI-TOF）质谱法用于测量其MW和MW分布。对于小分子化合物（MW 100 - 2000），电子喷雾电离（ESI）质谱法适用。质谱数据将与来自物理和成像测量的数据相关联，化学、物理和成像性质之间的关系将针对这类新的树枝状聚合物造影剂而被寻求。质谱数据是非常重要的和有价值的，在我们的新的PEG核树枝状造影剂的癌症成像的合成。